1. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-Dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74-88. doi:10.1016/j.brainresbull.2016.04.016
  2. Christian ST, Harrison R, Quayle E, Pagel J, Monti J. The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent. Biochemical Medicine. 1977;18(2):164-183. doi:10.1016/0006-2944(77)90088-6
  3. Saavedra JM, Axelrod J. Psychotomimetic N-Methylated Tryptamines: Formation in Brain in vivo and in vitro. Science. 1972;175(4028):1365-1366. doi:10.1126/science.175.4028.1365
  4. Axelrod J. Enzymatic Formation of Psychotomimetic Metabolites from Normally Occurring Compounds. Science. 1961;134:343. doi:10.1126/science.134.3475.343
  5. Dean JG, Liu T, Huff S, et al. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain. Sci Rep. 2019;9(1):1-11. doi:10.1038/s41598-019-45812-w
  6. Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells. Langmann T, ed. PLoS ONE. 2014;9(8):e106533. doi:10.1371/journal.pone.0106533
  7. Szabo A. Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Frontiers in Immunology. 2015;6. doi:10.3389/fimmu.2015.00358
  8. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022